High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy

Thomas H. Brannagan, Armin Alaedini, Douglas Gladstone

Research output: Contribution to journalArticle

Abstract

Patients with multifocal motor neuropathy (MMN) respond to intravenous immune globulin (IVIg) and cyclophosphamide, although the benefit is not sustained. High-dose cyclophosphamide can induce a remission in patients with autoimmune diseases, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We describe a patient with refractory MMN who improved with high-dose cyclophosphamide (50 mg/kg for 4 days) without stem cell rescue. Following treatment she discontinued IVIg. At a 6-month examination, her strength had improved and she had regained the ability to write. High-dose cyclophosphamide may be a successful treatment for patients with MMN refractory to other therapies.

Original languageEnglish (US)
Pages (from-to)246-250
Number of pages5
JournalMuscle and Nerve
Volume34
Issue number2
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Cyclophosphamide
Stem Cells
Intravenous Immunoglobulins
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Autoimmune Diseases
Therapeutics

Keywords

  • Autoimmune disease
  • Conduction block
  • Cyclophosphamide
  • GM1 antibodies
  • Multifocal motor neuropathy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy. / Brannagan, Thomas H.; Alaedini, Armin; Gladstone, Douglas.

In: Muscle and Nerve, Vol. 34, No. 2, 08.2006, p. 246-250.

Research output: Contribution to journalArticle

@article{8c9bf6b4713746b1870166ce86ee4af2,
title = "High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy",
abstract = "Patients with multifocal motor neuropathy (MMN) respond to intravenous immune globulin (IVIg) and cyclophosphamide, although the benefit is not sustained. High-dose cyclophosphamide can induce a remission in patients with autoimmune diseases, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We describe a patient with refractory MMN who improved with high-dose cyclophosphamide (50 mg/kg for 4 days) without stem cell rescue. Following treatment she discontinued IVIg. At a 6-month examination, her strength had improved and she had regained the ability to write. High-dose cyclophosphamide may be a successful treatment for patients with MMN refractory to other therapies.",
keywords = "Autoimmune disease, Conduction block, Cyclophosphamide, GM1 antibodies, Multifocal motor neuropathy",
author = "Brannagan, {Thomas H.} and Armin Alaedini and Douglas Gladstone",
year = "2006",
month = "8",
doi = "10.1002/mus.20524",
language = "English (US)",
volume = "34",
pages = "246--250",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy

AU - Brannagan, Thomas H.

AU - Alaedini, Armin

AU - Gladstone, Douglas

PY - 2006/8

Y1 - 2006/8

N2 - Patients with multifocal motor neuropathy (MMN) respond to intravenous immune globulin (IVIg) and cyclophosphamide, although the benefit is not sustained. High-dose cyclophosphamide can induce a remission in patients with autoimmune diseases, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We describe a patient with refractory MMN who improved with high-dose cyclophosphamide (50 mg/kg for 4 days) without stem cell rescue. Following treatment she discontinued IVIg. At a 6-month examination, her strength had improved and she had regained the ability to write. High-dose cyclophosphamide may be a successful treatment for patients with MMN refractory to other therapies.

AB - Patients with multifocal motor neuropathy (MMN) respond to intravenous immune globulin (IVIg) and cyclophosphamide, although the benefit is not sustained. High-dose cyclophosphamide can induce a remission in patients with autoimmune diseases, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We describe a patient with refractory MMN who improved with high-dose cyclophosphamide (50 mg/kg for 4 days) without stem cell rescue. Following treatment she discontinued IVIg. At a 6-month examination, her strength had improved and she had regained the ability to write. High-dose cyclophosphamide may be a successful treatment for patients with MMN refractory to other therapies.

KW - Autoimmune disease

KW - Conduction block

KW - Cyclophosphamide

KW - GM1 antibodies

KW - Multifocal motor neuropathy

UR - http://www.scopus.com/inward/record.url?scp=33746748791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746748791&partnerID=8YFLogxK

U2 - 10.1002/mus.20524

DO - 10.1002/mus.20524

M3 - Article

C2 - 16502421

AN - SCOPUS:33746748791

VL - 34

SP - 246

EP - 250

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 2

ER -